

35 **Summary**

36 **Background:**

37 Respiratory syncytial virus (RSV) is the leading cause of acute respiratory infection related 38 hospitalisations in infants (RSVh). Most of these infants are younger than 6 months old with 39 no known risk factors. An efficient RSVh prevention program should address both mothers 40 and infants, relying on Non-Pharmaceutical (NPI) and Pharmaceutical Interventions (PI). This 41 study aimed at identifying the target population for these two interventions. 42 **Methods:**

43 Laboratory-confirmed RSV-infected infants hospitalised during the first 6 months of life were 44 enrolled from the *Hospices Civils de Lyon* birth cohort (2014 to 2018). Clinical variables 45 related to pregnancy and birth (sex, month of birth, birth weight, gestational age, parity) were 46 used for descriptive epidemiology, multivariate logistic regression, and predictive score 47 development.

48 **Findings:**

49 Overall, 616 cases of RSVh in 45 648 infants were identified. Being born before the epidemic 50 season, prematurity, and multiparity were independent predictors of RSVh. Infants born in 51 January or June to August with prematurity and multiparity, and those born in September or 52 December with only one other risk factor (prematurity or multiparity) were identified as 53 moderate-risk, identifying the mothers as candidates for a first level NPI prevention program. 54 Infants born in September or December with prematurity and multiparity, and those born in 55 October or November were identified as high-risk, identifying the mothers and infants as 56 candidates for a second level (NPI and PI) intervention.

57 **Interpretation:**

58 It is possible to determine predictors of RSVh at birth, allowing to enrol early the target 59 population in a two-level RSV prevention intervention.

60 **Funding**

61 None.

62 **Research in context**

63 **Evidence before this study**

64 In infants, the global burden of disease caused by the respiratory syncytial virus (RSV) is 65 increasingly recognised. Nowadays the prevention programs are limited to the only licensed 66 drug, Palivizumab, a humanised monoclonal antibody that shows some benefit in preventing 67 RSV in high-risk infants. With the recent encouraging progress obtained using a maternal 68 vaccine candidate and long half-life monoclonal antibodies administered to newborns, as well 69 as the impact of Covid-19 non-pharmaceutical interventions on the RSV epidemic, there is an 70 urgent need to revisit this prevention paradigm from a much broader perspective.

71 **Added value of this study**

72 Using a hospital birth cohort (NOHAN strategy) split into a training and a testing dataset, we 73 were able to determine strong maternal and newborn predictors for the risk of RSV 74 hospitalisation. Month of birth, multiparity, and prematurity were sufficient to accurately 75 identify low-, moderate-, and high-risk groups in the validating cohort.

76 **Implications of all the available evidence**

77 Using the NOHAN strategy, future parents could be enrolled early during pregnancy follow-78 up in a health-related behaviour change program and then be proposed a vaccine boost for the 79 pregnant women or neutralizing monoclonal antibodies for the newborns. The thresholds for 80 triggering each intervention can be adjusted to the local epidemiology, the resources 81 available, and the evolving evidence concerning the cost-efficiency of the future 82 interventions. Stakeholders, healthcare professionals and policy makers must acknowledge 83 this opportunity when designing the future of RSV prevention programs.

85 **Introduction**

86 Respiratory syncytial virus (RSV) infection is the predominant cause of lower respiratory 87 tract infection (LRTI) in infants.^{1,2} In developed countries, RSV represents the leading cause 88 of hospitalisation during the first year of life,³ with up to 3% of all infants hospitalised every 89 year.⁴ Severe cases are more frequent in infants younger than 3 months⁵ and in infants with 90 known risk factors such as prematurity, lung or heart diseases, and immunodeficiency.⁶ 91 However, most infants hospitalised with RSV LRTI have no known risk factors.^{2,7,8}

92 Although RSV is now recognised as a major health burden worldwide, preventive approaches 93 remain limited. Non-Pharmaceutical Interventions (NPI) such as hand hygiene, breastfeeding, 94 and avoiding exposure to smoke or persons with acute respiratory illness are effective in 95 reducing the risk of infection with respiratory viruses in infants.^{9,10} The implementation of 96 NPI on a large scale during the COVID-19 pandemic, which strongly reduced the RSV 97 epidemic, 11 advocates for a stronger implementation of NPI. Pharmaceutical Intervention (PI) 98 is currently limited to the only licensed drug, Palivizumab, a humanised monoclonal antibody 99 that shows some benefit in preventing RSV in high risk infants.¹² More recently, encouraging 100 progress was made using a fusion protein nanoparticle vaccine administered to pregnant 101 women¹³ and long half-life monoclonal antibodies administered to newborns.¹⁴ Considering 102 the numerous PIs for RSV prevention currently being evaluated in clinical trials, there is a 103 reasonable hope that in coming years, PI will be broadly recommended to the general 104 population. 15

105 Nevertheless, successful implementation of the future prevention programs largely relies on 106 their capacity to target the mothers of infants with the higher risk. Recently, it has been 107 reported that prophylaxis regimens, adjusted for regional variations in terms of RSV 108 seasonality, may improve protection compared to the implementation of nationally 109 recommended regimens. $15,16$

5/24

110 Predictive models can help adjust the preventive action to the target population.¹⁷ Regarding 111 the risk of RSV-associated hospitalisation (RSVh), most of the published predictive models 112 have focused on high risk preterm infants.^{18–22} Only Houben *et al* proposed a simple 113 prediction rule that can identify infants at risk of RSV LRTI, but the cohort was limited in 114 size and the score designed only for clinical use.²³ 115 The Normative Outcome of Hospitalisation Assessment for Newborns (NOHAN) strategy 116 proposed herein aimed to adjust multi-level mother-infant interventions according to the risk

117 of RSVh at the general population level. The cut-off values can be adapted to balance the

118 resources available and the effectiveness of the preventive approach.

119

120 **Methods**

121 **Data sources**

122 Demographic and laboratory data were collected retrospectively. First, the administrative 123 registry of all infants born in the University Hospitals of Lyon (*Hospices Civils de Lyon*, 124 HCL) was used. Stillborn children or those living outside the region were excluded. This 125 database includes the following variables of interest: gender (male/female), month of birth, 126 gestational age (WG), maternal parity (primiparity/multiparity), plurality (single/multiple 127 gestation), childbirth type (vaginal birth/caesarean section), birth weight, and geographical 128 living area (postcode). Patients with at least one missing data for any studied variable were 129 excluded. The virology laboratory database was then used to identify, among all infants born 130 in the HCL and hospitalised during the RSV season with acute respiratory infection 131 symptoms, those with a respiratory sample positive for RSV. 24

132 Cases were defined as a new admission, during the first 6 months of life, to one of the 133 conventional paediatric hospital departments of the HCL with an RSV positive sample during 134 hospital stay. This 6-month follow-up period is in line with the preventive approaches 135 proposed herein (NPI, maternal vaccination program, monoclonal antibodies administered at

136 birth) which are mostly protective over the first 6 months of life.¹⁷ Presumed nosocomial 137 cases (i.e. cases observed during the birth stay) were not excluded considering that only few 138 cases were expected and that transmission from the community (mother, siblings, family) 139 could not be ruled out.

140

141 **Variable and categorical construction**

- 142 A term delivery was defined as a baby born > 37 weeks of gestation (WG) measured in weeks
- 143 of amenorrhoea (WA). Moderate and very preterm deliveries were defined as a baby born [≥]

144 32 WG and \leq 37 WG and a baby born \Box 32 WG, respectively.

145 Birth weight was categorised as either low or high when the value was outside 2 standard

146 deviations of the weight cohort distribution per WG. Month of birth was categorised into four

147 groups with increased incidence of RSVh during the first 6 months of life.

148 The choice to aggregate these two variables was made to match the categories used in 149 guidelines and clinical practice and to further facilitate the implementation of the.²⁵

150

151 **Cohort construction**

152 Overall, 45 648 infants were included in the study (2014 to 2018) from a catchment area of 153 1,370,678 inhabitants using public hospital registry data from the HCL (Figure 1).²⁶ To ensure 154 the stability of the score, the population studied was divided into three cohorts. The validating 155 cohort was defined as the 2018 birth cohort (n=8 709 infants born between January 2018 and 156 December 2018). The remaining cohort (2014 to 2017) was then randomly divided, with 157 equal-sized month of birth proportion, into a training cohort (70% of the remaining cohort, n= 158 25 858) and a testing cohort (30% of the remaining cohort, n=11 081). The validating cohort 159 was exposed to the 2018/2019 RSV season which was similar to the previous epidemics²⁷ 160 (Table 1).

162 **Identification of predictors of interest and predictive score generation**

163 To identify potential independent maternal RSVh predictors, all variables of the training 164 cohort were entered into a multivariate backwards stepwise logistic regression model to 165 remove predictors that did not significantly improve the fit of the logistic regression model 166 (based on a p-value of 0•10). The odds ratio (OR) values obtained from the final model were 167 rounded to the nearest integer and used to determine the score. The model was adjusted with 168 the year of birth and the hospital of birth (Table 2).

169

170 **Estimation of the model's performance and variance**

171 To evaluate the optimism-corrected performance values, the real-life model's performance 172 was quantified using the area under the receiver operating characteristic curve (AUROC) 173 (with 95% confidence interval) and the Brier score in the testing and validating cohorts. A k-174 fold (with $k=4$) cross validation approach was used to estimate the model's variance on the 175 training cohort. The distribution of month of birth was preserved in the split training sets 176 obtained using the k-fold cross validation. The validating cohort corresponds to a new set of 177 infants exposed to a new RSV epidemic and was used as an external control.

178 In the absence of any similar predictive model but based on references from research on other 179 medical predictive models, and given the potential cost-effectiveness of the preventive 180 program, an AUROCC > 0.70 was considered as evidence for good discrimination.^{28,29} A test 181 was considered significant when p value was lower than 0•05.

182

183 **Determining the cut-off values of the two-level preventive program**

184 The optimal cut-off value for the first level of intervention (NPI alone) was defined *a priori* 185 with minimal sensitivity and specificity values of 80 % and 20%, respectively. This cut-off 186 assumed a lower cost and effectiveness for NPI compared to PI. However, an NPI preventive 187 program may not be maintained all year-round if the perceived risk is too low. This

188 assumption was informed based on the results showing that the application of NPI measures

189 by French parents decreased over time during the COVID-19 crisis (CoviPrev survey).³⁰

190 The optimal cut-off value for the second level of intervention (NPI and PI) was defined *a* 191 *priori* with a minimal specificity value of 80%. This cut-off assumed a higher cost and 192 effectiveness for PI that would be then more suitable for a timely seasonal administration than 193 a year-round administration.³¹

194

195 **Statistical analyses**

196 Statistical analyses were performed using R software version 4.1.0 with the following 197 packages (ggplot2; reshape2; doBy; caret; scoring, pROC). The caret library was used for 198 data splitting. For the comparison of cohorts, p values were derived using the chi-squared test 199 for qualitative variables and the Student's t-test or ANOVA tests for quantitative variables.

200

201 **Ethics**

202 Parents of infants for whom hospitalisation data were used were informed of the study (aim of 203 the study, use of anonymised data, right to refuse participation) by postal mail. After this first 204 contact, data were anonymised. Parents of infants for whom hospitalisation data were used 205 were informed of the study (aim of the study, use of anonymised data, right to refuse 206 participation) by postal mail. After this first contact, data were anonymised. Authorisation 207 from Scientific and Ethical Committee of Hospices Civils de Lyon (Comité Scientifique et 208 Éthique des Hospices Civils de LYON CSE-HCL – IRB 00013204; Pr Cyrille Confavreux) 209 was obtained on 28/09/2021.

210

211 **Role of the funding source**

212 There was no funding source for this study. The corresponding author had full access to all 213 the data in the study and had the final responsibility for the decision to submit for publication.

214

215

216 **Results**

217 **Characteristics of the training, testing, and validating cohorts**

218 Several patients were missing data for gestational age and were excluded (572/46 220). The 219 population studied comprised 45 648 infants, 50•7% (23 140) were boys, 16•1% (7 354) were 220 born preterm (\leq 37 WG), 5•8% (2 641) from multiple births, 20•8% (9 497) were born by 221 caesarean section, and 43•7% (19 933) from multiparous mothers. The median (Interquartile 222 Range [IQR]) birth weight was 3 207 [2 920 -3 580] g. Among them, 616 were hospitalised in 223 their first 6 months of life with a laboratory-confirmed RSV infection, 53•7% (331) were 224 boys, 22•8% (140) were born preterm (\leq 37 WG), 7•3% (45) from multiple births, and 73•4% 225 (452) from multiparous mothers (Table 1). Among all cases, 0•8% (5) were suspected to be 226 nosocomial. The characteristics of the testing and training cohorts did not significantly differ. 227 The validating cohort did not significantly differ in terms of mean WG and birth weight when 228 compared to the testing and training cohorts. Significant differences in the frequencies of 229 month of birth, parity, gestation type, and childbirth type were observed between the 230 validating cohort and the testing and training cohorts (Table 1).

231

232 **Month of birth categorisation in the population studied**

233 Month of birth was categorised into four groups with increased incidence of RSVh during the 234 first 6 months of life. In the population studied 95•1% (586/616) of the cases were detected 235 from November to February with a peak during December (Figure 2). Mean (± Standard 236 Deviation SD) age at the time of hospitalisation was $2 \cdot 1$ ($\pm 1 \cdot 4$) months.

237 Incidence was 13•5 infants hospitalised in the first 6 months of life per 1000 infants (95% 238 Confidence Interval (CI) [12•0;15•0]). The incidence of RSVh in the first 6 months of life 239 was higher for those born just before the seasonal epidemic, from October to November (41•3

240 cases per 1000 infants (95% CI [37•0;46•0]) compared to those born in September and 241 December (23•0 cases per 1000 infants (95% CI [20•0;27•0]), as well as to those born in 242 January and June to August (7•53 cases per 1000 infants (95% CI [6•0;9•0]), and those born 243 February to May (0•81 cases per 1000 infants (95% CI $[0\text{-}0\cdot1\text{-}0]$; Figure 2). 244 In the model analysis, the month of birth was aggregated into these four groups of respective

245 increased RSVh incidence. The choice to aggregate this variable was done to facilitate the 246 implementation of the score in the patient and healthcare community in the context of 247 pregnancy.

248

249 **Maternal predictors of interest associated with increased risk of RSVh (training cohort)**

250 The multivariate logistic regression analysis in the training cohort retrieved three variables 251 significantly associated with hospitalisation: month of birth, gestational age, and parity. 252 Considering the month of birth, being born during October and November was associated 253 with the highest risk of RSVh (OR 46•35, 95% CI [24•40;102•73], p <0•001). Considering 254 the gestational age, being born \Box 32 WG was associated with a higher risk of RSVh (OR 255 3•26, 95% CI $[1\cdot80.5\cdot52]$, p <0 \cdot 001). Considering parity, multiparity was associated with a 256 higher risk of RSVh (OR 3.89, 95% CI [3•07; 4•97], p <0•001; Table 2). These variables, 257 along with the year of birth and the hospital of birth, were retained in the final predictive 258 model and used for the score construction.

259

260 **Performance of the RSVh predictive score in the testing and validating cohorts**

261 The final score value ranged from 0 to 53. The mean $(\pm SD)$ score was 16•98 $(\pm 16$ •42) in the

- 262 testing cohort and $18 \cdot 41$ ($\pm 19 \cdot 64$) in the validating cohort (external control).
- 263 The k-fold validation approach used in the training cohort to estimate the model's variance
- 264 found a mean AUROC value of 0•791 (95% CI [0•788; 0•793]) for the four split training

265 cohorts compared with a mean AUROC value of 0•821 (95% CI: [0•791; 0•850]) for the 266 validating cohort. The overlap between the two confidence intervals indicates a low variance. 267 The Hosmer-Lemehow chi-squared test used to assess the goodness of fit (p value $\langle 0 \cdot 001 \rangle$) 268 and the Brier score measured (value $= 0.0135$) in the validating cohort both indicated a good 269 performance of the predictive model.

270

271 **Identifying the target population for the two-level maternal-infant preventive program**

272 The optimal cut-off values of the RSVh predictive score for the first and second levels of 273 intervention were 14 and 28, respectively. The maternal population with an RSVh predictive 274 score below the first cut-off value (14) of intervention was defined as a low-risk group (Table 275 3). It encompasses all the mothers giving birth during the months of February to May and the 276 deliveries occurring during the months of January or June to August with no more than one 277 risk factor (prematurity or multiparity).

278 The maternal population with an RSVh predictive score above the first cut-off value (> 14) 279 and below the second cut-off value (< 28) of intervention was defined as a moderate-risk 280 group. It encompasses the deliveries occurring during the months of January or June to 281 August with prematurity and multiparity and the deliveries in September or December with 282 only one other risk factor (prematurity or multiparity).

283 The maternal population with an RSVh predictive score above the second cut-off value (> 28) 284 was defined as a high-risk group. It encompasses the deliveries in September or December 285 with prematurity and multiparity and all deliveries in October or November (Table 3).

286 When applied to the validating cohort, the predictive score identified 53% of infants as low-

287 risk (incidence 1•72 cases /1000 infants), 32% of infants as moderate-risk (incidence

288 18•92/1000 infants), and 15% of infants as high-risk (incidence 46•28/1000 infants; Table 3).

289

290 **Discussion**

291 In the present study, an original but simple approach was used to identify the target 292 population for a two-level preventive mother-infant intervention program based on maternal 293 and newborn risk factors.

294 The clinical predictors identified herein were already described in previous reports.^{19–21} 295 Month of birth is by far the strongest predictor of RSVh in the general birth cohort. This 296 finding is consistent with numerous previous observations reporting that infants born before 297 the RSV peak month have the highest RSVh admission rates.³³ Prematurity under 37 WG and 298 multiparity were also previously associated with increased RSVh risk.^{34,35}

299 The present approach differs from other RSVh prediction models.^{19–22} The novelty herein is 300 the use of RSVh risk factors that can be identified early in the pregnancy (month of birth and 301 multiparity) or at the infant's birth (WG). It allows the inclusion of target mothers and then 302 infants in a prevention program tailored to the infant's risk of RSVh. The first level entails a 303 reinforced behaviour change program (BCP) to promote good hygiene practices (hand 304 hygiene, breastfeeding, avoiding exposure to smoke and persons with acute respiratory 305 illness) and education on bronchiolitis. The second level is a pharmaceutical prevention 306 program that will integrate future licensed preventive drug interventions. These BCP and PI 307 can be introduced early during pregnancy follow-up so that the different healthcare workers 308 involved in the pregnancy, childbirth, and postnatal periods can repeatedly promote them to 309 the target population.

310 A major strength of this study was that all the diagnoses were PCR-confirmed, with only 311 minor missing values. Indeed, identifying cases based on diagnosis codes, such as admissions 312 for bronchiolitis, is neither fully specific nor sensitive. On one hand, bronchiolitis can be 313 caused by other respiratory viruses such as rhinoviruses, metapneumoviruses, and 314 influenzaviruses.³⁶ On the other hand, RSV admissions could be related to disease codes other 315 than bronchiolitis (sepsis, acute otitis). According to the hospital's local protocol, all infants 316 below the age of 1 year old hospitalised with acute respiratory infection, are tested for RSV

 317 during the RSV epidemic season.²⁴ A sensitivity analysis performed over one RSV season 318 (2016/2017) showed that 83•4% of all hospitalisations for bronchiolitis were due to RSV 319 (PCR-confirmed), while 11•5% were related to other viruses (5% did not have any sample 320 tested)³⁷. The second major strength of this work is that a complete case analysis was 321 performed, as there was only a small proportion of infants excluded for missing data. In 322 addition, dividing the population studied into three cohorts allowed a robust estimation of the 323 score's performance.

324 There are, however, some limitations to this work. First, the cost-effectiveness of the future 325 licensed preventive treatments remains to be determined. One consequence of the COVID-19 326 crisis may be a better integration and promotion of NPI in the prevention of viral respiratory 327 diseases. Although more costly, the future drugs in development will likely represent a more 328 efficient preventive approach if dedicated to high-risk infants. Therefore, this two-step 329 strategy is likely to be considered in the near future. Another limitation is that some known 330 risk factors (exposure to smoke, parent's education level, mother's age)³⁸ were not present in 331 the database and therefore not tested in the model. Palivuzimab use was also not measured in 332 this study. According to the French guidelines, Palivuzimab is recommended for premature 333 babies born before 29 WG or born before 32 WG with risk factors. This did not represent 334 more than 2% of the present birth cohort. Given that extremely premature infants are a small 335 subgroup of the general population, and that extreme prematurity was still a higher risk factor 336 than preterm and term births, it was assumed that the general model was not significantly 337 affected by the use of Palivizumab.

338 Using a hospital birth cohort, the NOHAN strategy allowed to determine strong maternal and 339 newborn predictors of RSVh risk. By using this strategy, future parents could be enrolled 340 early during pregnancy follow-up in a health-related BCP. The pregnant women could then be 341 proposed a vaccine boost, or neutralizing monoclonal antibodies could be administered to the 342 newborns. As demonstrated herein, the thresholds for triggering each level of intervention can

349

350 **Table 1. Demographic and clinical characteristics of the training, testing, and validating** cohorts.

352

353 Abbreviations: IQR, interquartile range, NA: Not appropriate for testing

355 **Table 2• Multivariate analysis of the risk factors for RSV-associated hospitalisation**

- 356 **during the first 6 months of life and predictive variables**
- 357

358 Abbreviations: OR, Odds Ratio; CI, confidence interval; NS, non-significant•

360 **Table 3: Characteristics of the low-, moderate-, and high-risk groups according to the**

predictive model•

362

363 *Calculated on the validating cohort. Incidence of infants hospitalised in the first 6 months of

364 life per 1000 infants

366 **Figure 1: Flowchart of the study**

367

368

370 **Figure 2• Incidence of infants hospitalised during the first six months of life according to**

371 **month of birth and number of hospitalisations per month in the studied population•**

372

373

374 Red line: Number of RSVh per month; Black column: Incidence of RSVh in the first 6

375 months of life per 1000 infants stratified according to month of birth.

376

378 **Contributors**

- 379 MJ, JSC, MB, CH contributed to the literature search, the figures and study design. MJ, JSC,
- 380 MB, CH, SCT, AFMD, DP YG, EJ, and BL contributed to data collection, MJ, JSC, MB have
- 381 verified the underlying data. All authors, contributed to the data interpretation, critically
- 382 reviewed the manuscript, and approved the final manuscript for submission.
- 383

384 **Declaration of interests**

- 385 We declare no competing interests.
- 386

387 **Data Sharing**

- 388 Aggregated data are available on reasonable request.
- 389

390 **Acknowledgement**

- 391 We acknowledge the contribution of the paediatric department, laboratory technical staff, the
- 392 BEHcl Team, and Véréna Landel (*Direction de la Recherche en Santé*, HCL Proof Reading
- 393 of the manuscript).
- 394

395 **References**

- 396 1 Ogra PL. Respiratory syncytial virus: the virus, the disease and the immune response. 397 *Paediatr Respir Rev* 2004; **5 Suppl A**: S119-126.
- 398 2 Hall CB, Weinberg GA, Iwane MK, *et al.* The burden of respiratory syncytial virus 399 infection in young children. *N Engl J Med* 2009; **360**: 588–98.
- 400 3 Shi T, McAllister DA, O'Brien KL, *et al.* Global, regional, and national disease burden 401 estimates of acute lower respiratory infections due to respiratory syncytial virus in young 402 children in 2015: a systematic review and modelling study. *Lancet* 2017; **390**: 946–58.
- 403 4 Deshpande SA, Northern V. The clinical and health economic burden of respiratory 404 syncytial virus disease among children under 2 years of age in a defined geographical area. 405 *Arch Dis Child* 2003; **88**: 1065–9.
- 406 5 Reeves RM, Hardelid P, Panagiotopoulos N, Minaji M, Warburton F, Pebody R. Burden of 407 hospital admissions caused by respiratory syncytial virus (RSV) in infants in England: A 408 data linkage modelling study. *J Infect* 2019; **78**: 468–75.

- 409 6 Welliver RC. Review of epidemiology and clinical risk factors for severe respiratory 410 syncytial virus (RSV) infection. *J Pediatr* 2003; **143**: S112-117.
- 411 7 Murray J, Bottle A, Sharland M, *et al.* Risk factors for hospital admission with RSV 412 bronchiolitis in England: a population-based birth cohort study. *PLoS One* 2014; **9**: 413 e89186.
- 414 8 Hardelid P, Verfuerden M, McMenamin J, Smyth RL, Gilbert R. The contribution of child, 415 family and health service factors to respiratory syncytial virus (RSV) hospital admissions 416 in the first 3 years of life: birth cohort study in Scotland, 2009 to 2015. *Euro Surveill* 2019; 417 **24**. DOI:10.2807/1560-7917.ES.2019.24.1.1800046.
- 418 9 Bracht M, Basevitz D, Cranis M, Paulley R, Paes B. Strategies for reducing the risk of respiratory syncytial virus infection in infants and young children: a Canadian nurses' 419 respiratory syncytial virus infection in infants and young children: a Canadian nurses' 420 perspective. *Neonatal Netw* 2012; **31**: 357–68.
- 421 10 Casalegno J-S, Ploin D, Cantais A, et al. Characteristics of the delayed respiratory 422 syncytial virus epidemic, 2020/2021, Rhône Loire, France. Euro Surveill 2021; 26: 423 2100630.
- 424 11 Baker RE, Park SW, Yang W, Vecchi GA, Metcalf CJE, Grenfell BT. The impact of 425 COVID-19 nonpharmaceutical interventions on the future dynamics of endemic infections. 426 *Proc Natl Acad Sci U S A* 2020; **117**: 30547–53.
- 427 12 Meissner HC, Welliver RC, Chartrand SA, *et al.* Immunoprophylaxis with palivizumab, a 428 humanized respiratory syncytial virus monoclonal antibody, for prevention of respiratory 429 syncytial virus infection in high risk infants: a consensus opinion. *Pediatr Infect Dis J* 430 1999; **18**: 223–31.
- 431 13 Madhi SA, Polack FP, Piedra PA, *et al.* Respiratory Syncytial Virus Vaccination during 432 Pregnancy and Effects in Infants. *New England Journal of Medicine* 2020; **383**: 426–39.
- 433 14 Griffin MP, Yuan Y, Takas T, *et al.* Single-Dose Nirsevimab for Prevention of RSV in 434 Preterm Infants. *New England Journal of Medicine* 2020; **383**: 415–25.
- 435 15 Cody Meissner H. Approaching the End of the Era of Uncontrolled Respiratory Syncytial 436 Virus Disease. *J Infect Dis* 2021; **223**: 737–9.
- 437 16 Artin B, Pitzer VE, Weinberger DM. Assessment and optimization of respiratory syncytial 438 virus prophylaxis in Connecticut, 1996-2013. *Sci Rep* 2021; **11**: 10684.
- 439 17 Mazur NI, Higgins D, Nunes MC, *et al.* The respiratory syncytial virus vaccine landscape: 440 lessons from the graveyard and promising candidates. *Lancet Infect Dis* 2018; **18**: e295– 441 311.
- 442 18 Kappen TH, Peelen LM. Prediction models: the right tool for the right problem. *Curr Opin* 443 *Anaesthesiol* 2016; **29**: 717–26.
- 444 19 Simões EAF, Carbonell-Estrany X, Fullarton JR, *et al.* A predictive model for respiratory 445 syncytial virus (RSV) hospitalisation of premature infants born at 33-35 weeks of 446 gestational age, based on data from the Spanish FLIP Study. *Respir Res* 2008; **9**: 78.

- 447 20 Sampalis JS, Langley J, Carbonell-Estrany X, *et al.* Development and validation of a risk 448 scoring tool to predict respiratory syncytial virus hospitalization in premature infants born
449 at 33 through 35 completed weeks of gestation. *Med Decis Making* 2008; **28**: 471–80.
- 449 at 33 through 35 completed weeks of gestation. *Med Decis Making* 2008; **28**: 471–80.
- 450 21 Paes B, Steele S, Janes M, Pinelli J. Risk-Scoring Tool for respiratory syncytial virus 451 prophylaxis in premature infants born at 33-35 completed weeks' gestational age in 452 Canada. *Curr Med Res Opin* 2009; **25**: 1585–91.
- 453 22 Blanken MO, Koffijberg H, Nibbelke EE, Rovers MM, Bont L, Dutch RSV Neonatal 454 Network. Prospective validation of a prognostic model for respiratory syncytial virus 455 bronchiolitis in late preterm infants: a multicenter birth cohort study. *PLoS One* 2013; **8**: 456 e59161.
- 457 23 Houben ML, Bont L, Wilbrink B, *et al.* Clinical prediction rule for RSV bronchiolitis in 458 healthy newborns: prognostic birth cohort study. *Pediatrics* 2011; **127**: 35–41.
- 459 24 Kramer R, Duclos A, VRS study group in Lyon, Lina B, Casalegno J-S. Cost and burden of 460 RSV related hospitalisation from 2012 to 2017 in the first year of life in Lyon, France. 461 *Vaccine* 2018; **36**: 6591–3.
- 462 25 Blencowe H, Cousens S, Oestergaard MZ, *et al.* National, regional, and worldwide 463 estimates of preterm birth rates in the year 2010 with time trends since 1990 for selected 464 countries: a systematic analysis and implications. *Lancet* 2012; **379**: 2162–72.
- 465 26 Évolution et structure de la population en 2015 − Population en 2015 | Insee. 466 https://www.insee.fr/fr/statistiques/3564100?sommaire=3561107 (accessed Feb 2, 2022).
- 467 27 Demont C, Petrica N, Bardoulat I, *et al.* Economic and disease burden of RSV-associated 468 hospitalizations in young children in France, from 2010 through 2018. *BMC Infect Dis* 469 2021; **21**: 730.
- 470 28 Greiner M, Pfeiffer D, Smith RD. Principles and practical application of the receiver-471 operating characteristic analysis for diagnostic tests. *Prev Vet Med* 2000; **45**: 23–41.
- 472 29 Youden WJ. Index for rating diagnostic tests. *Cancer* 1950; **3**: 32–5.
- 473 30 CoviPrev \Box : une enquête pour suivre l'évolution des comportements et de la santé mentale
474 pendant l'épidémie de COVID-19. https://www.santepubliquefrance.fr/etudes-et-COVID-19. https://www.santepubliquefrance.fr/etudes-et-475 enquetes/coviprev-une-enquete-pour-suivre-l-evolution-des-comportements-et-de-la-sante-476 mentale-pendant-l-epidemie-de-covid-19 (accessed Feb 2, 2022).
- 477 31 Liu D, Leung K, Jit M, Wu JT. Cost-effectiveness of strategies for preventing paediatric 478 lower respiratory infections associated with respiratory syncytial virus in eight Chinese 479 cities. *Vaccine* 2021; **39**: 5490–8.
- 480 32 Holberg CJ, Wright AL, Martinez FD, Ray CG, Taussig LM, Lebowitz MD. Risk factors 481 for respiratory syncytial virus-associated lower respiratory illnesses in the first year of life. 482 *Am J Epidemiol* 1991; **133**: 1135–51.
- 483 33 Wang X, Li Y, Vazquez Fernandez L, *et al.* Respiratory Syncytial Virus-Associated 484 Hospital Admissions and Bed Days in Children <5 Years of Age in 7 European Countries. 485 *J Infect Dis* 2022; : jiab560.

- 486 34 Rietveld E, Vergouwe Y, Steyerberg EW, *et al.* Hospitalization for respiratory syncytial 487 virus infection in young children: development of a clinical prediction rule. *Pediatr Infect* 488 *Dis J* 2006; **25**: 201–7.
- 489 35 Rossi GA, Medici MC, Arcangeletti MC, *et al.* Risk factors for severe RSV-induced lower 490 respiratory tract infection over four consecutive epidemics. *Eur J Pediatr* 2007; **166**: 1267– 491 72.
- 492 36 Papadopoulos NG, Moustaki M, Tsolia M, *et al.* Association of rhinovirus infection with 493 increased disease severity in acute bronchiolitis. *Am J Respir Crit Care Med* 2002; **165**: 494 1285–9.
- 495 37 Biot B, Gillet Y, Casalegno J-S. DETERMINANTS DE LA GRAVITE DES 496 BRONCHIOLITES A VRS. ANALYSE DES FACTEURS DE RISQUE 497 SOCIODEMOGRAPHIQUES, VIROLOGIQUES ET ENVIRONNEMENTAUX SUR LA 498 SAISON 2016-17 A LYON (Frech). 2018; published online June 15. 499 DOI:10.13140/RG.2.2.19956.48004.
- 500 38 Fitzpatrick T, McNally JD, Stukel TA, *et al.* Family and Child Risk Factors for Early-Life 501 RSV Illness. *Pediatrics* 2021; **147**: e2020029090.

502